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Mutations in HNRNPA1 encoding heterogeneous nuclear ribonucleoprotein (hnRNP) A1 are a rare cause of amyotrophic
lateral sclerosis (ALS) and multisystem proteinopathy (MSP). hnRNPA1 is part of the group of RNA-binding proteins
(RBPs) that assemble with RNA to form RNPs. hnRNPs are concentrated in the nucleus and function in pre-mRNA
splicing, mRNA stability, and the regulation of transcription and translation. During stress, hnRNPs, mRNA, and other
RBPs condense in the cytoplasm to form stress granules (SGs). SGs are implicated in the pathogenesis of (neuro-
)degenerative diseases, including ALS and inclusion body myopathy (IBM). Mutations in RBPs that affect SG biology,
including FUS, TDP-43, hnRNPA1, hnRNPA2B1, and TIA1, underlie ALS, IBM, and other neurodegenerative diseases.
Here, we characterize 4 potentially novel HNRNPA1 mutations (yielding 3 protein variants: *321Eext*6, *321Qext*6, and
G304Nfs*3) and 2 known HNRNPA1 mutations (P288A and D262V), previously connected to ALS and MSP, in a broad
spectrum of patients with hereditary motor neuropathy, ALS, and myopathy. We establish that the mutations can have
different effects on hnRNPA1 fibrillization, liquid-liquid phase separation, and SG dynamics. P288A accelerated
fibrillization and decelerated SG disassembly, whereas *321Eext*6 had no effect on fibrillization but decelerated SG
disassembly. By contrast, G304Nfs*3 decelerated fibrillization and impaired liquid phase separation. Our findings suggest
different underlying pathomechanisms for HNRNPA1 mutations with a possible link to clinical phenotypes.
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Introduction
Heterogeneous nuclear ribonucleoprotein (hnRNP) A1 is a member of  a large class of  RNA-binding pro-
teins (RBPs) that assemble with RNA to form ribonucleoproteins (RNPs). hnRNPs are evolutionarily 
conserved and are primarily localized to the nucleus, where they function in pre-mRNA splicing, mRNA 
stability, miRNA maturation, regulation of  transcription and translation, and telomere biogenesis (1–7). 
Mutations in HNRNPA1 encoding heterogeneous nuclear ribonucleoprotein (hnRNP) A1 are 
a rare cause of amyotrophic lateral sclerosis (ALS) and multisystem proteinopathy (MSP). 
hnRNPA1 is part of the group of RNA-binding proteins (RBPs) that assemble with RNA to form 
RNPs. hnRNPs are concentrated in the nucleus and function in pre-mRNA splicing, mRNA 
stability, and the regulation of transcription and translation. During stress, hnRNPs, mRNA, 
and other RBPs condense in the cytoplasm to form stress granules (SGs). SGs are implicated in 
the pathogenesis of (neuro-)degenerative diseases, including ALS and inclusion body myopathy 
(IBM). Mutations in RBPs that affect SG biology, including FUS, TDP-43, hnRNPA1, hnRNPA2B1, 
and TIA1, underlie ALS, IBM, and other neurodegenerative diseases. Here, we characterize 4 
potentially novel HNRNPA1 mutations (yielding 3 protein variants: *321Eext*6, *321Qext*6, 
and G304Nfs*3) and 2 known HNRNPA1 mutations (P288A and D262V), previously connected 
to ALS and MSP, in a broad spectrum of patients with hereditary motor neuropathy, ALS, and 
myopathy. We establish that the mutations can have different effects on hnRNPA1 fibrillization, 
liquid-liquid phase separation, and SG dynamics. P288A accelerated fibrillization and 
decelerated SG disassembly, whereas *321Eext*6 had no effect on fibrillization but decelerated 
SG disassembly. By contrast, G304Nfs*3 decelerated fibrillization and impaired liquid phase 
separation. Our findings suggest different underlying pathomechanisms for HNRNPA1 
mutations with a possible link to clinical phenotypes.
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Mutations affecting several RBPs, including FUS, TDP-43, hnRNPA1, hnRNPA2B1, matrin-3, and TIA1, 
are linked to amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multisystem proteinop-
athy (MSP), and hereditary inclusion body myopathy (hIBM) phenotypes (8, 9).
Missense mutations in the prion-like domain (PrLD) of  hnRNPA1 (p.D262V/N and p.N267S) are linked 
to ALS (MIM 615426) and MSP3 (MIM 615424) (10, 11). Additional ALS-linked mutations in hnRN-
PA1 are also in the PrLD (p.G264R) (12) or the nuclear localization sequence (p.P288S/A) (13, 14). The 
p.D262N mutation in HNRNPA1 was also reported in 2 families with IBM with a pure muscular phenotype, 
illustrating the heterogeneity of  consequences that arise from HNRNPA1 mutations. Several modest-sized 
genetic screenings failed to identify further HNRNPA1 mutations in 2485 patients with ALS, FTD, MSP, 
hIBM, or other myopathies, suggesting that disease-linked mutations in HNRNPA1 may be rare (15–19).
Stress granules (SGs) are at the nexus of  RBP pathology and neurodegenerative diseases (20–27). SGs 
are cytoplasmic membrane-less organelles that contain RNA and proteins, including several RBPs connect-
ed with neurodegeneration (22). SGs mostly contain mRNA transcripts, with approximately 80% of  the SG 
consisting of  mRNAs from essentially every expressed gene (28, 29). SGs also specifically contain small 
ribosomal subunits, translation initiation factors (eIF3, eIF4E, eIF4G), hnRNPs, and other RBPs, such as 
TIA1, HuR, and PABP (30). SGs accumulate upon stress via the formation and fusion of  numerous small 
condensates (31). Importantly, SGs dissolve once stress has passed, allowing SG components to return to 
performing their soluble function (31, 32). As a subcellular compartment, SGs are central to the pathogen-
esis of  degenerative diseases, as disease-causing mutations in RBPs are associated with accumulation of  
persistent SGs in ALS, FTD, and IBM (10, 21, 23, 26, 33, 34).
Neurodegenerative diseases are consistently characterized by pathological proteinaceous inclusions, a 
subset of  which contain SG markers (8, 9, 35, 36, 37). A good example is the deposition of  TDP-43, which 
is a prominent feature of  approximately 97% of  ALS cases, as well as nearly all cases of  sporadic IBM and 
hIBM (10, 24, 35–37). Pathological inclusion formation may be due to the failure of  SGs to disassemble 
(26). It is critical to distinguish whether inclusions observed in postmortem tissues represent persistent SGs 
or partially disassembled SGs or SG proteins are recruited to preformed inclusions, or some combination 
of  these possibilities (20). Indeed, the precise mechanisms by which specific RBPs become depleted from 
the nucleus and accumulate in cytoplasmic aggregates remain unclear.
Recent work on the broader group of  ventral horn, peripheral nerve, and muscle diseases — including 
inherited peripheral neuropathy (IPN), hereditary motor neuropathy (HMN), and ALS — has demonstrated 
a significant genetic overlap, including both pleiotropy and genetic heterogeneity. This overlap is illustrated 
by findings where causative genes do not exclusively give rise to the phenotype for which they were initially 
described, as for mutations in SETX, DCTN1, and SIGMAR1, which underlie both ALS and HMN (38–40).
Here, we present patients with 4 potentially novel HNRNPA1 mutations (yielding 3 protein variants: 
*321Eext*6, *321Qext*6, and G304Nfs*3) and 2 known HNRNPA1 mutations (P288A and D262V). 
These mutations expand the genetic and clinical spectrum of  hnRNPA1-associated neurodegenerative dis-
eases by demonstrating their involvement in complex IPN, atypical ALS, and myopathy. We establish that 
the mutations can have different effects on hnRNPA1 fibrillization, liquid-liquid phase separation (LLPS), 
and SG dynamics, indicating the possibility of  multiple underlying pathomechanisms for HNRNPA1 muta-
tions with a possible link to the clinical phenotypes. 
Results
Identification of HNRNPA1 mutations in 6 separate families
Mutations in the HNRNPA1 gene can result in a range of  neurodegenerative disorders (8, 10, 13–15, 17, 
41–43). For example, in a patient from family A with motor neuropathy, a heterozygous de novo splice site 
variation (c.908-2A>G) upstream of  the last exon of  HNRNPA1 was identified (Figure 1). cDNA analysis 
in this patient by PCR and Sanger sequencing revealed skipping of  the last exon, producing a transcript 
that was not degraded by nonsense-mediated decay (NMD), resulting in a truncated protein (p.G304Nfs*3) 
(Figures 1 and 2 and Supplemental Figure 1; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.148363DS1). To screen for additional hnRNPA1 mutations in patients, 
we surveyed a large cohort of  547 patients with distal HMN (dHMN), axonal Charcot-Marie-Tooth disease 
(CMT2), intermediate CMT (CMTi), spinal muscular atrophy (SMA), ALS, hereditary spastic paraplegia 
(HSP), and myopathy. Thus, we identified a missense variation (c.862C>G; p.P288A) in the index patient 
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of  family B that has been linked to ALS (Figure 1) (14). Whole-exome sequencing (WES) for this family 
did not reveal segregating mutations in other genes known for motor neuron diseases or related disorders. 
Therefore, the P288A mutation is the most likely cause of  disease in family B.
Four additional HNRNPA1 mutations were identified in families C–F (Figure 1). Whole-genome sequenc-
ing (WGS) in family C revealed a single-nucleotide variant in the HNRNPA1 stop-codon (c.961T>G; p.*321E-
ext*6) resulting in a stop-loss mutation without undergoing NMD. This mutation added 6 extra amino acids 
to the protein before ending at an alternative stop-codon (Figure 2). Both this stop-loss mutation and the splice 
variant from family A terminate on the same TAG sequence present in the WT 3′-UTR (Figure 2). In family D, 
a 500 bp deletion in HNRNPA1 was identified through trio WGS (Supplemental Figure 1D). This variant results 
in the same mRNA alteration as the variant in family A, yielding the same mutant protein (p.G304Nfs*3). For 
family E, WES in individual E:II:2 identified a known HNRNPA1 (c.785A>T; p.D262V) missense mutation, 
which was previously reported in a family with autosomal dominant myopathy and Paget’s disease of bone 
(PDB) (10, 42). We also identified a nearly identical mutation to *321Eext*6 linked to a similar phenotype in 
the isolated index of family F (p.*321Qext*6) (Figures 1 and 2 and Supplemental Table 2).
HNRNPA1 mutations are linked to a variety of phenotypes
Family A — (p.G304Nfs*3). At 15 years of  age, the isolated Polish patient (A:II:1) presented the first symp-
toms with wasting of  hand intrinsics. At 16, sural nerve biopsy showed very mild axonal neuropathy with 
secondary segmental demyelination. Electromyography (EMG) in median, ulnar, and peroneal nerves 
showed decreased amplitudes of  compound muscle action potentials (CMAPs) with nerve conduction 
velocities in the normal range, while no abnormalities were observed in sensory fibers. At 24, he displayed 
right-sided thoracic scoliosis, mild pes cavus, wasting of  the forearms and calves (lower third), and brisk 
deep tendon reflexes in the upper and lower limbs with intact sensory modalities. By age 40, he had severe 
wasting of  the distal muscles of  the upper and lower limbs. Despite a very clumsy gait with foot drop, he is 
still ambulant. Overall, his phenotype corresponds to an axonal motor-predominant neuropathy (dHMN).
Family B — (p.P288A). Patient B:II:1 is a 44-year-old woman of  Moroccan origin who developed painless 
proximal right arm weakness and wasting without sensory disturbances at age 22. Her father and paternal 
grandmother presented the same phenotype. Both died from respiratory failure around the age of  40. She 
was diagnosed with a very slowly progressive atypical ALS 4 years after symptom onset, based on the clinical 
Figure 1. Heterozygous HNRNPA1 mutations in 6 families. Pedigrees of families A–F with their respective mutations 
and the segregation of each by genotype, showing affected (black), unaffected (white), and hearsay-affected (gray) 
individuals. Arrows indicate probands.
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features with supportive neurophysiological findings: upper and lower motor neuron symptoms observed 
at the clinical examination and a chronic neurogenic pattern limited to the upper limb and tongue muscles 
recorded via EMG. Over time, she developed progressive weakness and wasting of  the left arm, respiratory 
insufficiency, and lower limb spasticity. Five years after symptom onset, she developed bulbar symptoms with 
dysarthria, rhinolalia, chewing difficulties, and eventually dysphagia for both liquids and solids. She required 
percutaneous endoscopic gastrostomy 3 years later. After 22 years of  disease progression, she is still walking 
without aid. Her 3 children are unaffected at the ages of  16, 21, and 25. At age 43, her older sister (patient 
B:II:2) presented with progressive bulbar symptoms, including dysarthria, tongue atrophy, and swallowing 
problems. She also presented upper motor neuron signs and right hand weakness with amyotrophy. Com-
bined, the phenotype in this family is that of  an atypical and slowly progressive ALS.
Family C — (p.*321Eext*6). Patient C:II:2 is of  Dutch origin and showed her first symptoms at 9 years 
of  age. She presented with hand function difficulties, mild facial weakness, and general fatigue by the age of  
12. Muscle weakness and atrophy were gradually progressive. She has been using a wheelchair since age 34. 
At age 45, muscle strength in upper and lower limbs had severely decreased, and reflexes were absent in all 
limbs. She also had a very severe facial weakness and subsequent dysarthria. An quadriceps muscle biopsy 
was performed, showing nonspecific myopathic changes with some angular fibers but no type grouping. 
Nerve conduction studies (NCSs) were normal apart from small CMAPs due to severe distal atrophy. 
Needle EMG was compatible with a myogenic process. The patient developed a mild dissociated vital 
hyposensitivity distally in the legs, but no abnormalities were noted on spinal MRI. The clinical diagnosis 
of  facio-scapulo-humeral muscular dystrophy could not be confirmed genetically.
The patient’s son (C:III:1) presented his first symptoms with a right-sided foot drop at the age of  8. 
At 13, he is ambulant and can still walk on his toes. However, heel walking is impossible. He shows slight 
wasting of  the left thenar and reduced muscle strength in the lower limbs. His reflexes are normal in all 
limbs. NCSs were normal and needle EMG revealed myopathic features. A needle biopsy of  the quadriceps 
muscle was performed at age 8, which showed mild and nonpathognomonic myopathic features. The phe-
notype in this family is compatible with a myopathy with distal and facial onset and severe proximal and 
bulbar weakness upon progression. The distal weakness, atrophy, and subsequent small CMAPs suggested 
an overlap with the dHMN disease spectrum, but myopathic features initially dominated the phenotype.
Family D — (p.G304Nfs*3). Individual D:II:1 is a 35-year-old woman of  Asian Indian origin who devel-
oped right hand weakness, pain when writing, and atrophy at age 22. At age 26, she was thought to have 
multifocal motor neuropathy based on her EMG but was treated with a trial of  intravenous immunoglobin 
without response. Her muscle biopsy at age 26 revealed vacuolar myopathy, notable for its myofibrillar 
Figure 2. Schematic overview of hnRNPA1 protein and mutations. hnRNPA1 contains 2 N-terminal RNA-recognition 
motifs (RRMs) and a C-terminal prion-like domain (PrLD), containing an arginine-glycine-glycine (RGG) motif and a 
proline-tyrosine nuclear localization signal (PY-NLS) that enables nuclear import. Mutations studied in this paper are 
shown. The effects of the frameshift and extension G304Nfs*3, *321Eext*6, and *321Qext*6 mutations at the protein 
level are shown in the zoom-in of amino acids 303–321.
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disorganization, moth-eaten fibers, rimmed vacuoles, and absence of  inflammation. Repeat EMG at age 
29 showed irritative distal myopathy. Her symptoms have been gradually progressive: at age 27, she noted 
right ankle weakness, which is now bilateral. Her exam is notable for mild right facial weakness, and her 
distal weakness is markedly asymmetric. Reflexes were initially preserved in the lower extremities but have 
diminished over time; there were no other upper motor neuron signs. She walks unassisted, has scapular 
winging, and has mild swallowing difficulties with normal speech. She has a restrictive lung function with 
predicted forced vital capacity of  76% and sleep-disordered breathing. Her creatine kinase has been 2-fold 
elevated. Cardiac MRI, electrocardiogram, and 14-day cardiac rhythm monitor were normal.
Family E — (p.D262V). Individual E:II:2 is an American male who developed asymmetric weakness of  
the right foot at around 36 years of  age, worsening over time to involve bilateral proximal leg weakness. He 
initially noticed difficulties with snow skiing and later had frequent tripping and falls. Over the course of  10 
years, there was slow progression of  bilateral leg weakness that now requires use of  a cane for ambulation. 
Currently, at age 48, the patient uses his arms to stand from sitting position and requires handrails when 
going up the stairs. He reports no weakness of  facial, neck, arm, or trunk muscles; numbness or tingling; 
dysphagia; difficulty with handwriting, handling utensils, or opening doors; shortness of  breath; bowel/
bladder dysfunction; diplopia; or muscle pain. NCS abnormalities were limited to low amplitude of  the 
right fibular CMAPs, whereas needle EMG revealed chronic myopathic changes proximally and distally in 
the leg. A muscle biopsy at age 45 showed chronic myopathy with rimmed vacuoles.
The patient’s mother (E:I:2) was diagnosed with PDB at the age of  48. Within 3 years she developed 
left leg weakness that gradually progressed to involve both legs. She is currently using a wheelchair. She has 
normal arm strength and normal cranial nerve function, and a muscle biopsy was consistent with myopathy 
with inclusion bodies. The index patient has 6 unaffected siblings (34–50 years old). The overall phenotype 
in this family is consistent with inclusion body myositis.
Family F — (p.*321Qext*6). Patient F:I:1 is of  Belgian origin and presented first at the age of  12 years 
with muscle atrophy in the hands, with subsequent progressive wasting of  the lower limbs starting dis-
tally before also involving proximal muscles. At his last examination at the age of  64, this patient used a 
wheelchair with profound generalized weakness resulting in de facto quadriplegia. Reflexes were lost in all 
Table 1. Summary of the molecular features of hnRNPA1 mutants
hnRNPA1 protein (p.) WT G304Nfs*3 P288A *321Eext*6 D262V
Yeast model






Cytoplasmic foci Cytoplasmic foci Cytoplasmic foci
In silico prediction












Droplet formation at 




concentration of >20 
μM
Droplet formation at 




concentration of >5 μM
Similar LLPS propensity 




~10% of hnRNPA1 is 
incorporated into SGs




No change in SG 
incorporation


























complete in 60-minute 
recovery period
Changes compared with WT are indicated in bold; literature references are presented for experiments not performed in this study.
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extremities. In addition to contractures in the lower limbs and bilateral pes equinovarus, the patient displayed 
marked facial weakness. Respiration was severely limited, requiring cough assist and noninvasive home 
ventilation (bilevel positive airway pressure). The patient also made use of  a percutaneous endoscopic 
gastrostomy. A biopsy of  the tibialis anterior muscle at the age of  13 years showed myogenic alterations 
consisting of  marked diameter variation, selective type 1 fiber atrophy, increased centralized nuclei, and the 
presence of  rimmed vacuoles. A biopsy of  the fibularis superficialis nerve was strictly normal. NCSs and 
needle EMG did not show neurogenic changes and were consistent with a distally predominant myopathy. 
The patient died at age 64. The family history for this patient is negative for neuromuscular disorders, 
making this an isolated case. The clinical presentation fits with a progressive myopathy with onset in the 
distal limbs. A clinical diagnosis of  distal myopathy of  Welander type or Nonaka type was suggested. No 
mutation in UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (GNE) was found.
Comparable in vitro transcription and translation of hnRNPA1 mutants
To verify that the alternatively terminating variants were not subject to NMD, mRNA sequences for the 
G304Nfs*3 (family A) and *321Eext*6 (family C) variants were assessed by PCR amplification from exon 
8 into the 3′-UTR on cDNA from patient lymphoblasts. Gel electrophoresis and di-deoxy sequencing 
confirmed exon 11 skipping for the G304Nfs*3 splice variant (Supplemental Figure 1A). mRNA for the 
G304Nfs*3 and *321Eext*6 variants was present, indicating the absence of  NMD and suggesting that these 
genes are transcribed and likely translated in patients (Supplemental Figure 1, B and C). RNA sequencing 
confirmed altered splicing in family D, resulting in the same protein as family A (Supplemental Figure 1D). 
Next, hnRNPA1 plasmids were constructed for N-terminally V5 tagged WT hnRNPA1 cDNA, as well as 
P288A, G304Nfs*3, and *321Eext*6 mutations, and each protein was transiently expressed in Henrietta 
Lacks (HeLa) cells. Immunoblotting confirmed translation of  WT hnRNPA1 and the mutant proteins. As 
expected, the G304Nfs*3 mutation produced a shorter protein, whereas the *321Eext*6 mutation yielded 
a longer protein (Supplemental Figure 1E). The P288A mutation translated into a protein of  similar size 
to WT hnRNPA1 (Supplemental Figure 1E). Thus, these patient-derived mutant mRNA transcripts can be 
translated into mutant hnRNPA1 protein in cells.
WT and mutant hnRNPA1 confer toxicity in yeast
Next, we assessed the hnRNPA1 variants in a yeast model of  hnRNPA1 aggregation and toxicity (10). The 
hnRNPA1 PY-NLS is not decoded by the yeast nuclear import machinery, and hnRNPA1 localizes to the 
cytoplasm in yeast (44–46). hnRNPA1 and hnRNPA1D262V form cytoplasmic aggregates in yeast and are tox-
ic, which phenocopies pathological events in MSP (10, 47). Here, it is important to note that in MSP cases 
caused by mutations in VCP or hnRNPA2, it is the WT version of  hnRNPA1 that undergoes cytoplasmic 
aggregation (10). Thus, expression of  WT hnRNPA1 in yeast recapitulates the cytoplasmic mislocalization 
and aggregation of  WT hnRNPA1 that occurs in MSP caused by mutations in hnRNPA2 or VCP (10).
We transformed WT or mutant hnRNPA1 on a galactose-induced expression vector and serially dilut-
ed yeast onto glucose (no expression of  hnRNPA1), sucrose/galactose (1:1; moderate expression of  hnRN-
PA1), or galactose-containing agar plates (high expression of  hnRNPA1). Expression of  WT or mutant 
hnRNPA1 on sucrose/galactose (1:1) and galactose media was toxic (Figure 3A). Immunoblot confirmed 
that hnRNPA1 variants were robustly expressed in yeast on galactose media (Figure 3, B and C). Thus, in 
yeast, the hnRNPA1 variants displayed similar toxicity to WT hnRNPA1, suggesting that the cytoplasmic 
localization of  hnRNPA1 is pathogenic for these variants in yeast (Figure 3A).
Next, we assessed the aggregation of mutant hnRNPA1. hnRNPA1, hnRNPA1D262V, hnRNPA1P288A, and 
hnRNPA1*321Eext*6 formed cytoplasmic foci (Figure 3D). By contrast, hnRNPA1G304Nfs*3 displayed more diffuse 
localization, although cytoplasmic foci were still evident (Figure 3D). G304Nfs*3 was expressed to similar levels 
as the other hnRNPA1 proteins (Figure 3, B and C). Thus, hnRNPA1G304Nfs*3 may be less aggregation prone than 
hnRNPA1, hnRNPA1D262V, hnRNPA1P288A, and hnRNPA1*321Eext*6 while conferring similar toxicity (Figure 3A).
Differential fibrillization and LLPS propensity of hnRNPA1 variants
Our yeast work suggested that hnRNPA1 variants may differ in their propensity to self-assemble. To investi-
gate how the mutations affect the fibrillization propensity of  hnRNPA1, we first examined WT hnRNPA1 
and the disease-associated mutants with ZipperDB (48). ZipperDB is a structure-based threading algo-
rithm, which scores 6 amino acid segments for their propensity to form 2 self-complementary β-strands 
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termed “steric zippers” that form the spine of  amyloid fibrils. Hexapeptides with Rosetta energy of  lower 
than –23 kcal/mol are predicted to form steric zippers, with lower energy predicting higher amyloidogenic-
ity. ZipperDB predicted that the P288A mutation introduces a new steric zipper (285-SSGAYG-290) that 
could increase the fibrillization propensity (Figure 4A). By contrast, G304Nfs*3 deletes a large stretch of  
Figure 3. hnRNPA1 variants are toxic and aggregate in yeast. (A) GFP-tagged hnRNPA1 variants are toxic when expressed in yeast. Yeast spotting assays 
compare the toxicity of hnRNPA1 variants by plating yeast at serially diluted concentrations. hnRNPA1 variants were expressed from a galactose-inducible 
promoter for 72 hours. Expression of hnRNPA1 is repressed when cells are grown on glucose (left panel), then moderately induced on sucrose/galactose 
(middle panel), and strongly induced on galactose (right panel). (B) Western blot confirms the expression of GFP-tagged hnRNPA1 variants in yeast after 
8 hours in galactose. Phosphoglycerate kinase (PGK) is used as loading control. (C) GFP signal was quantified from 3 separate blots and normalized to 
the PGK signal of the respective sample. The variability in hnRNPA1 expression is not significant as measured by 1-way ANOVA using Dunnett’s multiple 
comparisons test. (D) Yeast cells expressing GFP-tagged WT and mutant hnRNPA1. hnRNPA1, hnRNPA1D262V, hnRNPA1P288A, and hnRNPA1*321Eext*6 formed 
cytoplasmic foci. hnRNPA1G304Nfs*3 displayed more diffuse localization in yeast, although cytoplasmic foci could be found.
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Figure 4. hnRNPA1 variants can exhibit altered propensity for fibrillization and LLPS. (A) ZipperDB calculates the propensity of hexapeptide fragments 
to form steric zippers (48). Steric zippers, which are self-complementary β-sheets that form the backbone of amyloid fibrils, are predicted to form when 
the Rosetta energy of a hexapeptide is below the empirically determined “high fibrillization propensity” threshold of −23 kcal/mol (48). P288A intro-
duces a potent steric zipper (285-SSGAYG-290) that could increase the fibrillization propensity. G304Nfs*3 deletes several potent steric zippers, which 
could reduce fibrillization propensity. (B and C) GST-TEV-hnRNPA1 and disease variants (5 μM) were incubated with TEV protease in A1 assembly buffer 
to initiate fibrillization. Reactions were agitated at 1200 rpm or 0–24 hours at 25°C. Fibrillization was monitored by electron microscopy (B). Scale bar, 0.5 
μm. Alternatively, hnRNPA1 fibrillization kinetics were determined by sedimentation analysis (C) where the amount of hnRNPA1 in the pellet fraction was 
quantified. Values represent average ± SEM (n = 3–6). (D) Representative differential interference contrast (DIC) microscopy images of hnRNPA1 droplets 
formed by different hnRNPA1 variants. Droplets were formed by combining the indicated hnRNPA1 variant at the indicated concentration in a LLPS buffer 
and were imaged immediately after all components had been added. Scale bar: 25 μm. (E) Phase diagram of hnRNPA1 variants showing the hnRNPA1 
concentrations where LLPS occurs. hnRNPA1 and hnRNPA1P288A form droplets at concentrations of 2.5 μM or higher. hnRNPA1*321Eext*6 forms droplets at con-
centrations of 5 μM or higher. hnRNPA1G304Nfs*3 forms droplets at concentrations of 20 μM or higher. At each concentration, a colored circle indicates droplet 
formation, whereas a black asterisk indicates no droplets.
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steric zippers present in the C-terminal portion of  the PrLD, which could reduce multivalency and aggre-
gation propensity (Figure 4A). Finally, the *321Eext*6 mutation did not change the steric zipper landscape, 
with ZipperDB predicting a similar fibrillization propensity to WT hnRNPA1 (Figure 4A).
To assess the fibrillization propensity, we purified GST-TEV–tagged versions of  the proteins from E. 
coli (10). Fibrillization of  purified GST-TEV-hnRNPA1 was initiated by incubating with TEV protease to 
remove the GST tag (10). Fibrillization kinetics were then monitored by sedimentation analysis, and the final 
structures that formed were imaged via electron microscopy (10). hnRNPA1P288A assembled into fibrils more 
rapidly than WT hnRNPA1 (Figure 4, B and C), consistent with the ZipperDB prediction (Figure 4A). Thus, 
P288 disfavored β-sheet interactions between hnRNPA1 proteins that drive fibrillization (Figure 4A) (49–
51). P288 is also a critical component of  the hnRNPA1 PY-NLS, which is important for nuclear localization 
(52, 53). Therefore, in cells, the P288A mutation contributes to increased cytoplasmic hnRNPA1 mislocal-
ization and aggregation. As predicted by ZipperDB, hnRNPA1*321Eext*6 exhibited similar fibrillization kinetics 
to WT hnRNPA1 (Figure 4, B and C). Strikingly, hnRNPA1G304Nfs*3 displayed decelerated fibrillization, with 
only a few fibrils apparent after 24 hours (Figure 4, B and C), again in line with ZipperDB predictions (Fig-
ure 4A) and reduced formation of  cytoplasmic foci in yeast (Figure 3D). Thus, P288A accelerates hnRNPA1 
fibrillization, whereas *321Eext*6 has minimal effect, and G304Nfs*3 reduces fibrillization.
hnRNPA1 is a component of SGs, which form via LLPS (10, 25). Similar to other PrLD-containing RBPs 
in SGs, purified hnRNPA1 forms liquid droplets spontaneously upon macromolecular crowding (25). In the 
presence of a crowding agent, WT hnRNPA1 forms liquid droplets at concentrations of 2.5 μM or greater (Fig-
ure 4, D and E). hnRNPA1P288A showed similar LLPS properties to WT hnRNPA1 (Figure 4, D and E), where-
as hnRNPA1*321Eext*6 had slightly reduced ability to undergo LLPS, as no droplets formed at 2.5 μM (Figure 
4, D and E). Thus, the features that drive fibrillization of hnRNPA1 (such as steric zippers) do not necessarily 
have the same effect on LLPS (54). By contrast, hnRNPA1G304Nfs*3 exhibited reduced LLPS as liquid droplets 
were only observed at 20 μM (Figure 4, D and E). Moreover, hnRNPA1G304Nfs*3 droplets were smaller than 
those formed by hnRNPA1, hnRNPA1P288A, and hnRNPA1*321Eext*6 (Figure 4, D and E). Thus, the G304Nfs*3 
mutation perturbs hnRNPA1 LLPS and fibrillization, likely by reducing PrLD multivalency (Figure 4A).
hnRNPA1 mutants modulate SG dynamics
In human cells, hnRNPA1 localizes to SGs in response to specific stressors (10, 55, 56). Thus, we expressed 
WT or mutant GFP-tagged hnRNPA1 in HeLa cells and subjected these cells to environmental stress-
ors. WT hnRNPA1 was predominantly nuclear upon arsenite stress (Figure 5, A and B). G304Nfs*3 and 
*321Eext*6 mutations did not affect incorporation of  hnRNPA1 into arsenite-induced SGs, whereas 
hnRNPA1P288A showed significantly greater incorporation into SGs (Figure 5, A and B). This result is con-
sistent with previous reports that mutations in the hnRNPA1 PY-NLS reduce hnRNPA1 nuclear import 
and enhance incorporation into SGs (13, 14, 57). With heat stress, we observed greater WT hnRNPA1 
incorporation into SGs (Supplemental Figure 2). The *321Eext*6 mutation did not affect hnRNPA1 incor-
poration into heat shock–induced SGs, whereas hnRNPA1P288A showed significantly greater incorporation 
(Supplemental Figure 2). G304Nfs*3 reduced incorporation of  hnRNPA1 into SGs upon heat shock, sug-
gesting that P288A and G304Nfs*3 mutations have opposite effects on hnRNPA1 incorporation into SGs.
To assess how hnRNPA1 mutations affect SG dynamics, we established a live-cell assay that monitors 
SG assembly and disassembly kinetics during a controlled heat pulse. Thus, we generated a U2OS cell 
line in which CRISPR/Cas9 was used to tag endogenous G3BP1 (a SG marker) with tdTomato (58). We 
transiently transfected these cells with EGFP-tagged hnRNPA1 (WT or mutant forms). Although none of  
the hnRNPA1 mutants had a significant effect on the number or assembly rate of  SGs, we observed muta-
tion-dependent effects on SG disassembly kinetics. When SGs were induced by a 30-minute heat shock, 
the hnRNPA1P288A slightly delayed disassembly relative to WT hnRNPA1 (Figure 5C). Extending the heat 
shock to 60 minutes further delayed SG disassembly for hnRNPA1P288A, and now hnRNPA1*321Eext*6 also 
decelerated SG disassembly (Figure 5, D and E). Cells expressing WT hnRNPA1 or hnRNPA1G304Nfs*3 
showed nearly complete SG disassembly after 60-minute recovery (Figure 5, D and E). Consistent with 
our pure protein data (Figure 4D), hnRNPA1G304Nfs*3 elicited faster SG disassembly than WT hnRNPA1 
(Figure 5, D and E). However, approximately 50% of  cells expressing hnRNPA1P288A or hnRNPA1*321Eext*6 
failed to disassemble SGs in this time frame (Figure 5, D and E). This delay suggests that incorporation of  
hnRNPA1P288A or hnRNPA1*321Eext*6 into SGs alters their dissolution. Moreover, these findings suggest that 
the severity of  stress can reveal differences between hnRNPA1 variants.
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Figure 5. Localization and stress granule dynamics of the hnRNPA1 mutants. (A and B) HeLa cells were transiently transfected with WT or mutant EGFP-
tagged hnRNPA1 and subjected to arsenite stress (0.5 mM sodium arsenite, 30 minutes). Cells were fixed and stained with eIF3η (red) and DAPI (blue). 
Confocal images were taken for partition coefficient analysis. Scale bar: 10 μm (original magnification, ×10 for the insets). Error bars represent mean ± SD 
(n = 55, 43, 40, and 58 cells for WT, P288A, G304Nfs*3, and *321Eext*6, respectively). ****P < 0.0001, by ordinary 1-way ANOVA with Dunnett’s multiple 
comparisons test. (C) U2OS cells expressing tdTomato-tagged endogenous G3BP1 were transiently transfected with WT or mutant EGFP-tagged hnRNPA1 
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Finally, we evaluated how hnRNPA1D262V, which is associated with MSP and was identified in family E in 
this study, altered SG formation (10). As with the other mutations tested here, hnRNPA1 incorporation into 
SGs was similar for WT hnRNPA1 and hnRNPA1D262V (Supplemental Figure 3A). However, similar to hnRN-
PA1P288A or hnRNPA1*321Eext*6, hnRNPA1D262V significantly delayed SG disassembly (Supplemental Figure 3, B 
and C). Thus, hnRNPA1 mutations can have variable effects on SG disassembly kinetics. Specifically, P288A, 
D262V, and *321Eext*6 can delay SG disassembly, whereas G304Nfs*3 can accelerate SG disassembly.
Discussion
Here, we identified and characterized potentially novel and previously described HNRNPA1 mutations in 
patients with atypical ALS, HMN, distal myopathy, and MSP3 (Supplemental Table 2). In 6 families, we 
identified stop-loss mutations *321Eext*6 and *321Qext*6 leading to extension of  the protein; a splice site 
mutation and a 500 bp deletion, both leading to skipping of  the last exon, resulting in a truncated protein, 
G304Nfs*3; a known missense mutation causal for ALS (P288A) in a family with an atypical slowly progres-
sive ALS phenotype; and the known MSP3 D262V variant in a family with myopathy (14). These mutations 
are all in the hnRNPA1 PrLD, supporting previous findings that PrLD alterations can have important bio-
logical consequences (10, 50). Despite the larger cohort that was surveyed, we only identified 4 HNRNPA1 
mutations, suggesting that HNRNPA1 mutations are rare.
Mutations in HNRNPA1, though rare, show great clinical heterogeneity. Patients in family A (G304Nfs*3) 
and B (P288A) present with phenotypes of  pure motor neuron disorders without sensory involvement and 
with pyramidal, bulbar, and upper motor neuron involvement spanning the spectrum of dHMN to atypical 
(juvenile) ALS. The slow progression of  disease in these patients is striking. Patients in family B remain 
ambulant even 15–20 years after disease onset, unlike typical ALS cases. Patients in family C (*321Eext*6) 
present a phenotype that is compatible with a distal-onset myopathy with facial weakness with relatively 
faster progression, with the eldest patient using a wheelchair by age 34. Some neurogenic features suggest an 
overlap with the motor neuron spectrum in this family. Family F (*321Qext*6) shows a myopathic phenotype 
with pronounced facial weakness similar to family C. These families harbor the similar mutations *321Eext*6 
(family C) and *321Qext*6 (family F). The myopathic phenotype in family E (D262V) is similar to the previ-
ously reported family carrying the D262V mutation. These families demonstrate that a broader range of  phe-
notypes is associated with pathogenic HNRNPA1 variants than was previously appreciated. Based on these 
findings, we suggest that it could be beneficial to test patients with a range of  motor neuron diseases, including 
dHMN, atypical and typical ALS, as well as (distal) myopathy and MSP phenotypes, for pathogenic HNRN-
PA1 variants. Defining the mechanism by which hnRNPA1 mutations manifest pathologically is essential for 
understanding and treating diseases in which these mutations are present.
Several RBPs with PrLDs, including hnRNPA1, are implicated in neurodegenerative diseases (8, 10, 35, 
47, 59–63). Disease-linked PrLD mutations can exacerbate the propensity of  the RBP to form self-seeding 
fibrils, resulting in cytoplasmic aggregation and persistent SGs (8, 10, 23, 41). In addition to negative gain-of-
function consequences of  PrLD mutations, there are also loss-of-function consequences to having a mutated 
PrLD. In the case of  hnRNPA1, the PrLD participates in pre-mRNA splicing, stable RNA binding, optimal 
RNA annealing activity, and protein-protein interactions (64, 65). Thus, PrLD mutations may also perturb 
normal hnRNPA1 function.
We assessed the intrinsic fibrillization and LLPS propensity of 4 of the HNRNPA1 mutations identified 
here (Table 1). P288A is predicted to accelerate fibrillization because proline can act as a gatekeeper residue 
that inhibits fibrillization by inducing a local twist (structural constraint) that is incompatible with cross-β struc-
ture (49–51). ZipperDB predicted that the P288A mutation results in a new potent steric zipper in the PrLD, 
which we show causes more rapid fibrillization. This change in the biophysical properties of hnRNPA1P288A 
is compounded by its impaired nuclear import (13). Indeed, the P288A mutation alters the critical proline of  
and subjected to heat shock (43°C, 30 minutes; orange shading) and allowed to recover at 37°C for 2 hours. Line graph represents the percentage of cells 
with visible tdTomato-G3BP1 puncta over time. Error bars represent mean ± SEM (n = 10, 17, 23, and 18 videos for WT, P288A, G304Nfs*3, and *321Eext*6, 
respectively). Blue shaded area indicates time points at which P288A mutant was statistically significantly different from WT. **P < 0.01 by 2-way ANOVA 
with Dunnett’s multiple comparisons test. (D and E) U2OS cells expressing tdTomato-tagged endogenous G3BP1 were transiently transfected as in C and 
subjected to heat shock (43°C, 60 minutes; orange shading) and allowed to recover at 37°C for 90 minutes. White dotted lines (D) delineate hnRNPA1-pos-
itive cells; scale bar indicates 10 μm. Line graph (E) represents the percentage of cells with visible tdTomato-G3BP1 puncta over time (n = 56, 34, 48, and 35 
videos for WT, P288A, G304Nfs*3, and *321Eext*6, respectively). Blue shaded area indicates time points at which each mutant was statistically significantly 
different from WT. *P < 0.05, **P < 0.01 (colors correspond to the respective mutants), by 2-way ANOVA with Dunnett’s multiple comparisons test. 
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the PY-NLS of hnRNPA1, which weakens the interaction with its nuclear import receptor, karyopherin-β2 
(Kapβ2) (53, 66). Thus, Kapβ2 is predicted to be less able to chaperone and disaggregate hnRNPA1P288A in the 
cytoplasm and return hnRNPA1P288A to the nucleus (66). Thus, enhanced intrinsic fibrillization and reduced 
interaction with Kapβ2 likely combine to render P288A pathogenic. In this way, the hnRNPA1P288A variant 
resembles ALS-linked FUSP525L where the critical proline of the FUS PY-NLS is mutated to leucine, which 
reduces the interaction with Kapβ2 (66, 67) and simultaneously directly promotes FUS aggregation (68).
ZipperDB predicted that the *321Eext*6 mutation does not alter the steric zipper landscape of  hnRN-
PA1. Accordingly, hnRNPA1*321Eext*6 exhibited similar fibrillization propensity as WT hnRNPA1. Finally, 
ZipperDB revealed that the G304Nfs*3 mutation deletes several potent steric zippers from the PrLD, which 
would reduce the multivalency of  the PrLD and reduce fibrillization. Indeed, hnRNPA1G304Nfs*3 exhibited 
reduced fibrillization in vitro. The decelerated fibrillization of  G304Nfs*3 is also observed in other mutant 
proteins connected with neurodegenerative disease. For example, the α-synuclein variant, A30P, which causes 
familial Parkinson’s disease (69), assembles into fibrils more slowly than WT α-synuclein (70). However, α-sy-
nucleinA30P accesses toxic oligomeric forms more rapidly than WT α-synuclein and populates these forms for 
longer before forming fibrils (70). A similar situation could arise with G304Nfs*3, with the extended lag phase 
of  fibrillization causing prolonged exposure to toxic oligomeric species.
In addition to forming stable fibrils, the hnRNPA1 PrLD promotes LLPS, which contributes to SG 
assembly (25, 54). hnRNPA1G304Nfs*3 exhibited reduced LLPS propensity, whereas hnRNPA1P288A and hnRN-
PA1*321Eext*6 were more similar to WT hnRNPA1. The reduced LLPS propensity of  hnRNPA1G304Nfs*3 could 
lead to loss of  hnRNPA1 function for processes that require hnRNPA1 LLPS, such as (but not limited to) 
maintaining SG stability (71–74).
Upon stress, hnRNPA1 partitions into cytoplasmic SGs, only to disperse again once stress dissipates. 
HNRNPA1 mutations also affect SG dynamics. Fibrillization-prone hnRNPA1P288A increased hnRNPA1 accu-
mulation in SGs and decelerated SG disassembly. Conversely, hnRNPA1G304Nfs*3, which shows impaired LLPS 
and fibrillization, facilitated more rapid SG disassembly. hnRNPA1*321Eext*6 exhibited similar fibrillization pro-
pensity to WT hnRNPA1 but delayed SG disassembly. hnRNPA1*321Eext*6 might slow SG disassembly via the 
C-terminal -ELGNKA extension, which may enable SG-stabilizing interactions.
Intracellular RBP aggregates are a hallmark of  ALS/FTD. However, different hypotheses have been 
advanced to explain how mutations in these proteins cause neurodegeneration. On the one hand, patho-
logical aggregates can cause a toxic gain of  function (75). On the other hand, mutations can lead to loss of  
normal function (75). Loss of  hnRNPA1 function could affect splicing, translation, miRNA biogenesis, and 
transcription of  many targets.
Our findings suggest that disease-linked HNRNPA1 mutations can have different effects on fibrillization, 
LLPS, and SG dynamics while still causing phenotypes within the known spectrum of disease. Thus, rather 
than a universal mechanism defined by accelerated fibrillization as with D262V, P288A, and D262N (10), it 
seems likely that there are multiple disease-causing mechanisms at work as suggested by the *321Eext*6 and 
G304Nfs*3 variants. Which critical hnRNPA1 functions are most affected and how they affect physiological 
pathways remains to be investigated. Further research into the differences in normal functions affected by the 
mutations might help explain the phenotypic variation observed for HNRNPA1 mutations. The identification 
of  additional mutations in hnRNPA1 in degenerative disorders of  motor neurons and muscle will also help 
understand the underlying pathomechanisms. Based on our results, we suggest that there is not one unifying 
mechanism but rather a spectrum of disturbances, including fibrillization propensity, LLPS propensity, and 
SG dynamics, each of  which may elicit cellular dysfunction and degeneration.
Methods
Study participants. We describe 6 families: 3 with isolated patients and 3 with a dominant inheritance of motor 
neuron or muscle disorders (Supplemental Table 2). Samples from these 6 families were subjected to next-gen-
eration sequencing. Additionally, 547 patients diagnosed with dHMN, CMT2, CMTi, SMA, ALS, HSP, or 
myopathy were screened for HNRNPA1 mutations. For all patients and family members, high-molecular-weight 
genomic DNA was extracted from blood samples using standard methods.
Next-generation sequencing. Next-generation sequencing (WES or WGS) was performed on high-molecu-
lar-weight genomic DNA from families A–F (Supplemental Table 1). Subsequent processing and filtering were 
performed in the separate research or diagnostic facilities using similar approaches and general practices used for 
identification of rare disease-causing genetic variants (Supplemental Table 1).
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The de novo heterozygous 500 bp deletion identified in family D encompassing exon 9 of  HNRNPA1 
(NM_002136.4: c.907+15_*5-68del) (76, 77) was confirmed via a quantitative PCR assay. Transcriptome 
sequencing (RNA-Seq) was performed on D:II:1 cultured fibroblasts to assess the effect of  the deletion on the 
HNRNPA1 mRNA transcript (78). RNA-Seq revealed skipping of  exon 9 (https://varsome.com/transcript/
hg19/NM_002136.4), which is predicted to result in a truncated protein (p.G304Nfs*3) (Figure 2 and Supple-
mental Figure 1D). Additionally, RNA-Seq did not show a decrease in HNRNPA1 mRNA expression levels 
compared with controls, indicating the aberrant transcript escapes NMD (Supplemental Figure 1D).
Requests for deidentified sequencing data sets for the families included in this study should be directed 
to the corresponding author, JB.
HNRNPA1 variant screening. A Multiplex Amplification of  Specific Targets for Resequencing (Agilent) 
assay was designed to screen for mutations in all coding regions and exon-intron boundaries of  the HNRN-
PA1 gene in an additional 547 patients. Multiplex PCRs and following barcoding steps were performed on 
a Veriti AB machine (Life Technologies). Libraries were sequenced on a MiSeq Platform (Illumina) using 
v3 chemistry with read lengths of  2 × 300 bp. For read alignment, variant calling, annotation, and filtering, 
GATK, SAMtools, and GenomeComb were used. For possible pathogenic HNRNPA1 variants, WES was 
performed to exclude other pathogenic variants, and Sanger sequencing was used for validation and segrega-
tion analysis in all available family members.
Plasmid generation. mRNA for index patient family A, index patient family C, and a control individual 
was extracted from lymphoblast cell lines by RNeasy Mini Kit (QIAGEN). cDNA was generated by reverse 
transcription using the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific). cDNA was 
used for PCR amplification of  HNRNPA1 (NM_002136.3) with primers containing sequences suitable for 
subsequent Gateway Cloning Technology (Thermo Fisher Scientific). pDONR221 was used as the entry vec-
tor. The P288A variant from family B was introduced into the WT HNRNPA1 entry clone by site-directed 
mutagenesis (79). The G304Nfs*3 mutation from families A and D and the *321Eext*6 variant from family 
C were cloned by direct amplification of  the patient cDNA. The mRNA for the variant from family D is the 
same as the variant for family A, and thus the same plasmid was used. The entry clones were subcloned into 
a pLenti backbone with N-terminal V5- or EmGFP-tag for stable transduction and puromycin selection. Tem-
plates were checked by Sanger sequencing.
Yeast plasmids with each hnRNPA1 variant were generated by cloning into the pAG416GAL-GFP-ccdB 
vector backbone using Gateway reactions (Thermo Fisher Scientific). Mutations were generated via Quik-
Change Site-Directed Mutagenesis Kit (Agilent) and verified by DNA sequencing. Plasmids for bacterial protein 
expression were generated by cloning into a pDUET-GST vector backbone. Mutations were made via Quik-
Change Site-Directed Mutagenesis Kit (Agilent) and verified by DNA sequencing.
Mammalian cell culture. HeLa (CCL-2) and U2OS (HTB-96) cells were from ATCC; cultured in DMEM 
(HyClone) supplemented with 10% fetal bovine serum (FBS; HyClone; SH30396.03), 1× GlutaMAX (Thermo 
Fisher Scientific; 35050061), and 50 U/mL penicillin and 50 μg/mL streptomycin (Gibco; 15140–122); and 
maintained at 37°C in a humidified incubator with 5% CO2. U2OS cells expressing tdTomato-tagged endoge-
nous G3BP1 have been described (58). Cells were authenticated by short tandem repeat profiling.
Western blot. HeLa cells were incubated at 37°C in a humidified atmosphere with 5% CO2. Cells were cul-
tured in MEM, with l-glutamine and Earle’s salts (Thermo Fisher Scientific), with 10% heat-inactivated FBS, 
1% l-glutamine, and 1% penicillin-streptomycin. Transient transfection of  HeLa cells with WT and mutant 
HNRNPA1 lentiviral plasmids was performed using polyethylenimine. Transfected HeLa cells were cultured 
for 24 hours before collection.
After transfection, HeLa cells (4 × 106) were pelleted and lysed with RIPA lysis buffer (150 mM NaCl, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 1% NP-40, 50 mM Tris-HCl pH 7.4) supple-
mented with protease inhibitors (Roche Diagnostics). A total of 12.5 μg protein was run on a NuPAGE Novex 
4%–12% Bis-Tris Protein Gel (Thermo Fisher Scientific). Primary antibody mouse anti-V5 (1:5000; Life Tech-
nologies R960-25) and secondary goat anti–mouse IgG2a horseradish peroxidase (1:10,000; Southern Biotech, 
catalog 1081-05) were used, and visualization was performed with enhanced chemiluminescence detection 
(Pierce ECL Plus Western Blotting Substrate, Thermo Fisher Scientific). Equal loading was assessed by rabbit 
α-tubulin primary antibody (1:5000; Abcam rabbit polyclonal IgG ab4074) with goat anti–rabbit IgG horserad-
ish peroxidase secondary antibody (1:10,000; Southern Biotech, catalog 4030-05).
Yeast cells transformed with the appropriate plasmid were grown at 30°C in galactose-containing media 
for 8 hours to induce protein expression. Cultures were normalized to an OD600 = 0.6, and 6 mL of cells 
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were harvested. Yeast lysates were extracted by incubation with 0.1 M NaOH at room temperature for 5 min-
utes. Lysates were mixed with SDS-sample buffer, boiled for 5 minutes, and subjected to Tris-HCl SDS-PAGE 
(4%–20% gradient, Bio-Rad), followed by transfer to a PVDF membrane (MilliporeSigma). Membranes were 
blocked in Odyssey blocking buffer (LI-COR) for 1 hour at room temperature. Primary antibody incubations 
were performed at 4°C overnight. After washing with PBS with 1% Tween (PBST), membranes were incubat-
ed with fluorescently labeled secondary antibodies at room temperature for 1 hour, followed by washing with 
PBST. Proteins were detected using an Odyssey Fc dual-mode imaging system (LI-COR). Antibodies used 
were rabbit polyclonal anti-GFP (MilliporeSigma, catalog G1544), mouse monoclonal anti-PGK1 (Thermo 
Fisher Scientific, catalog 459250), and fluorescently labeled anti-mouse and anti-rabbit secondary antibodies 
(LI-COR, catalog nos. 926-32210 and 926-68071, respectively).
Yeast transformation and spotting assays. All experiments were performed using Saccharomyces cerevisiae strain 
BY4741 (MATa, his3Δ1, leu2Δ0, met15Δ0, uraΔ30) (80). The PEG/lithium acetate method was used to trans-
form yeast with plasmid DNA (81). For spotting assays, yeast cells were grown overnight at 30°C in liquid 
media containing raffinose (SRaf/-Ura) until they reached log or midlog phase. Cultures were then normalized 
for OD600; serially diluted; spotted onto synthetic solid media containing glucose, sucrose/galactose (1:1), or 
galactose lacking uracil; and were grown at 30°C for 2–3 days. Yeast experiments were performed in triplicate.
Protein purification. hnRNPA1 proteins were purified as described (10, 82, 83). Protein was centrifuged at 
16,100g for 10 minutes at 4°C to remove any aggregated material before use in fibrillization and LLPS assays. 
After centrifugation, the protein concentration in the supernatant was determined by Bradford assay (Bio-Rad).
In vitro fibrillization assays. hnRNPA1 (5 μM) fibrillization (100 μL reaction) was initiated by addition of  
2 μg of  TEV protease in A1 assembly buffer (40 mM HEPES-NaOH at pH 7.4, 150 mM KCl, 5% glycerol, 
1 mM DTT, and 20 mM glutathione). hnRNPA1 fibrillization reactions were incubated at 25°C for 24 
hours with agitation at 1200 rpm in an Eppendorf  Thermomixer, at which time fibrillization was complete 
with approximately 100% of  the hnRNPA1 in the aggregated state. For sedimentation analysis, at indicat-
ed times, fibrillization reactions were centrifuged at 16,100g for 10 minutes at 4°C. Supernatant and pellet 
fractions were resolved by SDS-PAGE and stained with Coomassie Brilliant Blue, and the relative amount 
in each fraction was determined by densitometry in ImageJ (NIH). Fibrillization assays were performed 
in triplicate. For electron microscopy, fibrillization reactions (10 μL) were adsorbed onto glow-discharged 
300-mesh Formvar/carbon-coated copper grids (Electron Microscopy Sciences) and stained with 2% (w/v) 
aqueous uranyl acetate. Excess liquid was removed, and grids were air-dried. Samples were viewed using a 
JEOL 1010 transmission electron microscope.
In vitro LLPS assays. hnRNPA1 liquid droplets were formed by incubating hnRNPA1 in the absence of TEV 
protease at the indicated concentration in LLPS buffer (40 mM HEPES-NaOH at pH 7.4, 150 mM NaCl, 5% 
glycerol, 1 mM DTT, and 20 mM glutathione, 10% dextran) at 25°C. Protein samples were spotted onto a cover-
slip immediately after all components had been added and imaged using a Leica DMI6000 by DIC microscopy.
Immunofluorescence. HeLa cells were seeded on 8-well glass slides (MilliporeSigma). Cells were transfected 
24 hours after seeding using FuGENE 6 (Promega) with EGFP-tagged or enhanced yellow fluorescent pro-
tein–tagged (EYFP-tagged) hnRNPA1 constructs. Cells were stressed 24 hours after transfection with 500 μM 
sodium arsenite (MilliporeSigma) for 30 minutes. Cells were then fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences), permeabilized with 0.5% Triton X-100, and blocked in 5% bovine serum albumin. Pri-
mary antibodies used were against G3BP1 (611127; BD Biosciences) and eIF3η (sc-16377; Santa Cruz Bio-
technology). For visualization, the appropriate host-specific Alexa Fluor 555 or 647 (Molecular Probes, catalog 
no. A31570 or A21447, respectively) secondary antibody was used. Slides were mounted using ProLong Gold 
Antifade Reagent with DAPI (Life Technologies). Images were captured using a Leica TCS SP8 STED 3X 
confocal microscope (Leica Biosystems) with a 63× objective. Images were quantified by automated puncta 
analysis using CellProfiler software (Broad Institute). Cells were segmented using DAPI and G3BP1 channels, 
and granules were identified using G3BP1 and eIF3η channels. Integrated intensities of nucleus, cytoplasm, 
and granules were measured. Yeast cells that had been transformed with the indicated EGFP-tagged hnRNPA1 
protein or vector were grown for 8 hours in galactose-containing media, pelleted, and imaged using a Leica DM 
IRBE microscope before being processed using ImageJ (NIH).
Live-cell time-lapse imaging. tdTomato-G3BP1–knockin U2OS cells were seeded in glass-bottomed, poly-
d-lysine–coated, 35 mm dishes (MatTek Corporation). Cells were transfected 24 hours after seeding using 
FuGENE 6 (Promega) with EGFP-tagged or EYFP-tagged hnRNPA1 constructs. The dish was transferred 
48 hours after transfection to an Opterra II swept-field confocal microscope (Bruker) system with a stage top 
1 5
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(14):e148363  https://doi.org/10.1172/jci.insight.148363
incubator with 5% CO2 and 60× objective with an objective heater (Bioptechs), preheated to 37°C. The system 
was left to equilibrate for 5–10 minutes before imaging was initiated.
For time-lapse imaging, using PrairieView software with perfect focus engaged, multipoint images were 
taken every 30 seconds with both 488 and 560 nm lasers. Two minutes into imaging, the objective temperature 
was raised to 43°C to begin heat shock; 30 or 60 minutes later, the temperature was lowered back to 37°C to 
alleviate stress, and cells were imaged until granules disappeared, or after 2–3 hours passed. Cells with equiva-
lent expression levels of hnRNPA1 were selected for further analysis.
Live-cell analysis. Live-cell imaging analysis was performed manually. Only hnRNPA1-positive viable 
cells that did not have td-Tomato G3BP1-positive granules prior to the 2-minute mark were evaluated. Cells 
were considered granule negative at the beginning of  the video and were considered granule positive at the 
frame in which distinct cytoplasmic granules were visible. The frame at which cytoplasmic granules were 
no longer visible was defined as the time point at which cells were again SG negative. Images were analyzed 
using ImageJ (NIH). The percentage of  cells that were considered granule positive was determined and 
graphed at each time point.
Statistics. Statistical analysis was performed in GraphPad Prism. Comparisons of the mean of each group 
with the mean of a control group were performed by 1-way ANOVA with Dunnett’s multiple comparison test. 
For comparing mean of control group with the means of other groups in each time point, 2-way ANOVA with 
either Sidak’s or Dunnett’s multiple-comparison test was performed. P values were considered significant at 
values less than 0.05 unless otherwise stated. 
Study approval. All patients or their legal representatives signed informed consent forms before enrollment. 
The ethics review boards of  the University of  Antwerp and Antwerp University Hospital; the Mossakowski 
Medical Research Centre of  the Polish Academy of Sciences; the University Hospitals St-Luc of  the Universi-
ty of  Louvain; Radboud University Medical Center; the Leiden University Medical Center; Stanford Univer-
sity; the University of  North Carolina at Chapel Hill; and Antwerp University Hospital approved this study.
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